Illumina, Inc. (ILMN)
$
137.6
+2.82 (2.05%)
Key metrics
Financial statements
Free cash flow per share
6.4103
Market cap
20.6 Billion
Price to sales ratio
4.8039
Debt to equity
1.0819
Current ratio
1.4251
Income quality
6.0000
Average inventory
582.5 Million
ROE
0.2998
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis, reflecting its robust operational framework. The earnings per share (EPS) is reported at -$7.69 indicating the company's profitability on a per-share basis, while the net total of other income and expenses is -$346,000,000.00 reflecting non-core financial activities. Operating expenses amount to $3,694,000,000.00 encompassing various operational costs incurred, and the total costs and expenses for the company are $5,205,000,000.00 reflecting its overall spending. Additionally, the weighted average number of shares outstanding is $159,000,000.00 highlighting the company's shareholder base and underscoring its financial health and stability. With a diverse range of products and services, Illumina serves a broad set of customers in genomic research centers, academic institutions, government laboratories, hospitals, and commercial entities in the pharmaceutical, biotechnology, and molecular diagnostics sectors. The company was incorporated in 1998 and is headquartered in San Diego, California, ensuring a strong presence in crucial markets. The stock is reasonably priced at $102.75 appealing to a broad range of investors looking for opportunities in the biotech field. Furthermore, the stock has a high average trading volume of $1,840,019.00 indicating strong liquidity and investor interest. With a mid-range market capitalization of $21,025,280,000.00 the company is a steady performer in the market. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape and driving advances in genetic analysis technologies. Additionally, it belongs to the Healthcare sector, which is experiencing rapid growth and innovation, positioning Illumina as a vital contributor to advancements in life sciences, oncology, and other emerging market segments.
Is Illumina, Inc. (ILMN) a good investment?
Investing in Illumina, Inc. (ILMN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Illumina, Inc. (ILMN)'s stock forecast?
Analysts predict Illumina, Inc. stock to fluctuate between $68.70 (low) and $153.06 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Illumina, Inc.'s market capitalization?
As of 2025-12-19, Illumina, Inc.'s market cap is $21,025,280,000, based on 152,800,000 outstanding shares.
How does Illumina, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Illumina, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Illumina, Inc. (ILMN) stock?
To buy Illumina, Inc. (ILMN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ILMN. Place an order (Market, Limit, etc.).
What is the best time to invest in Illumina, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Illumina, Inc. stock ever split?
Illumina, Inc.'s last stock split was 2:1 on 2008-09-23.
How did Illumina, Inc. perform in the last earnings report?
Revenue: $4,372,000,000 | EPS: -$7.69 | Growth: -0%.
Where can I find Illumina, Inc.'s investor relations reports?
Visit https://www.illumina.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Illumina, Inc.?
You can explore historical data from here
What is the all-time high and low for Illumina, Inc. stock?
All-time high: $526 (2021-08-16) | All-time low: $68.70 (2025-04-09).
What are the key trends affecting Illumina, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Illumina (ILMN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
prnewswire.com
SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 The presentation is scheduled for 7:30 a.m.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
prnewswire.com
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif.
zacks.com
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
defenseworld.net
AlphaCore Capital LLC purchased a new position in shares of Illumina, Inc. (NASDAQ: ILMN) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,177 shares of the life sciences company's stock, valued at approximately $208,000. A number
seekingalpha.com
Illumina, Inc. ( ILMN ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC Okay. Good morning, everybody.
prnewswire.com
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale Recent collaborations and projects including Genomics England and PRECISE-SG100K highlight advancements in proteomic profiling across diverse populations and research areas SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the broadest coverage of the blood proteome on the market at the lowest cost per protein target for more than 40 customers across 16 sites globally. Labs of all sizes are creating powerful layers of omic data for a range of diseases that enrich datasets generated by biobank programs around the world.
prnewswire.com
SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases.
seekingalpha.com
Illumina, Inc. ( ILMN ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Conor Noel McNamara - VP of Investor Relations Jacob Thaysen - CEO & Director Ankur Dhingra - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Daniel Leonard - UBS Investment Bank, Research Division Patrick Donnelly - Citigroup Inc., Research Division Mason Carrico - Stephens Inc., Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, ladies and gentlemen.
See all news
